Skip to main content

Multiple Myeloma

Hightower’s comprehensive research has led to huge advancements in multiple myeloma treatments.


About Multiple Myeloma Clinical Trials

Multiple myeloma is a cancer of the plasma cells, a type of white blood cell found in bone marrow. It affects over 30,000 people in the United States each year. This cancer disrupts healthy bone production, leading to bone pain, fatigue, and increased risk of fractures. While treatment options exist, there’s a continuous need for innovative therapies to improve patient outcomes.

At Hightower Clinical, we understand the challenges faced by multiple myeloma patients. We are actively involved in conducting clinical trials for this disease to learn more about the safety and dosing of the study drug, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.

Current Status

Not Recruiting

Study Count


Frequently Asked Questions

What is the purpose of a multiple myeloma clinical trial?

Multiple myeloma clinical trials aim to evaluate new treatments, therapies, or interventions for individuals diagnosed with multiple myeloma.

How can I participate in a multiple myeloma clinical trial?

Eligibility criteria for multiple myeloma clinical trials vary depending on the specific goals and design of the study. Factors such as age, stage of myeloma, previous treatments, overall health status, and other medical conditions may influence eligibility.

What should I consider before participating in a multiple myeloma clinical trial?

Before enrolling in a multiple myeloma clinical trial, patients should carefully consider several factors, including the potential risks and benefits of participating, the specific goals and design of the study, and the requirements and commitments involved.